SC
KNSA icon

Savant Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Savant Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$992K Sell
15,478
-526
-3% -$27.3K ﹤0.01% 889
2026
Q1 		$771K Buy
16,004
+9,128
+133% +$404K ﹤0.01% 713
2025
Q4 		$284K Buy
6,876
+1,129
+20% +$45.3K ﹤0.01% 1083
2025
Q3 		$223K Buy
+5,747
New +$187K ﹤0.01% 1186

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Savant Capital's KNSA Position: Q2 2026 in Review

Savant Capital reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.3% in Q2 2026, selling an estimated $27.3K and leaving 15,478 shares worth $992K. The position accounts for ﹤0.01% of the portfolio, ranked #889.

Savant Capital first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Savant Capital held 15,478 shares of Kiniksa Pharmaceuticals worth $992K as of Q2 2026.
  • Savant Capital sold 526 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $27.3K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #889 holding.
  • Savant Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.